The present findings strengthen the rationale to raise the concentrations of circulating GDF15 in early PCOS, for example by a SPIOMET-like intervention that attenuates ectopic adiposity, insulin resistance and low-grade inflammation, without necessarily lowering body weight. Here, GDF15 is linked to polycystic ovary syndrome.